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Summary.-An analysis of survival time of 57 West European patients with hepato-
cellular carcinoma was carried out to define which of several possible factors (age,
sex, cirrhosis and raised serum a-foetoprotein (AFP)) influenced survival. Although
survival was significantly longer in younger patients (P<0-02) and in patients with
normal serum AFP (P<001), multivariate analysis showed that significant variation
in survival time is better explained by the single factor, the presence of cirrhosis,
than by AFP level. This does not seem to apply for patients with this tumour in
Africa and the Far East, and there may be a fundamental difference in the natural
history of the tumour between high- and low-incidence areas.
THE DEVELOPMENT of a radioimmuno-
assay for accurate quantification of a-
foetoprotein (AFP) capable of detecting
levels as low as 2-10 ng/ml in normal sub-
jects, has shown that the range of serum
levels in patients with hepatocellular car-
cinoma is much wider than initially
thought. Many have concentrations
< 3000 ng/ml, which would not be detect-
able by an immunodiffusion technique
(Purves et al., 1968; Rouslati et al., 1972;
Chayvialli & Ganguli, 1973; Kohn &
Weaver, 1974; Alpert, 1976). Although
most workers hvae not been convinced
that the level ofAFP is related to survival
(Vogel et al., 1974; Okuda, 1976) we have.
gained the impression that patients with
AFP concentrations within the normal
range (40%o in a recent series of consecu-
tive patients (Johnson et al., 1978a)) do
have a better prognosis. Most patients
with raised AFP concentrations have
underlying cirrhosis whereas in 900% of
those with normal values the liver outside
the tumour is normal (Johnson et al.,
1978a). It is therefore possible that a
poorerprognosis in the former group might
relate primarily to the underlying liver
disease.
In this study we have carried out multi-
variate statistical analysis of the relation-
ship between serum AFP and survival in
57 patients with hepatocellular carcinoma,
using the Cox regression method (Cox
et al., 1977). The simultaneous effects of
other variables (cirrhosis, age and sex)
were also assessed.
PATIENTS AND METHODS
57 patients with hepatocellular carcinoma
presented to the Liver Unit, King's College
Hospital, between 1976 and 1979. All were
European, 43 were male, and ages ranged
from 16 to 76 (mean 52 + 16 (s.d.)) years. In
all cases the tumour had been confirmed
histologically, and 29 patients had an under-
lying cirrhosis, also shown histologically. In
the other 28, cirrhosis was excluded either on
liver biopsy or at laparotomy or autopsy.
AFP was measured by radioimmunoassav
(The Radiochemical Centre, Amersham,
Buckinghamshire, U.K.). At presentation 41
patients had a raised serum AFP concentra-
tions, ranging widely from 65 to 508,000 ng/
ml. They were therefore divided into 3 groups:AFP AND SURVIVAL IN LIVER CANCER
11 patients (27%) had AFP values 10-1000
ng/ml (slightly raised); 24 patients (58%) had
values 1000-100,000 ng/ml (moderately
raised); and 6 (15%) had markedly raised
values (> 100,000 ng/ml).
When tumour was confined to a single lobe
with no evidence of extrahepatic spread (5
patients), treatment was by hepatic lobar
resection. No extrahepatic spread was de-
tected in 5 other patients receiving ortho-
topic liver transplantation. The other
patients received cytotoxic drugs: Adria-
mycin, according to a standard dose regimen
(Johnson et al., 1978b) or VP 16 213 (180 mg/
m2 i.v. for 3 consecutive days fortnightly).
STATISTICAL METHODS
The influence of serum AFP was assessed
by comparing survival of those with normal
(16) and raised (41) serum AFP; by compar-
ing survival of those with slightly, moder-
ately and markedly raised serum AFP and,
finally, by determining the relationship be-
tween each patient's initial AFP level and his
survival time. The effect ofage was studied by
comparing survival in those under 50 years
ofage (18) and those over 50 (39), and also by
individually correlating age with survival.
Simple actuarial survival curves were con-
structed for patients with and without
raised serum AFP, for the groups with and
without underlying cirrhosis and for the
groups with no underlying liver disease, with
and without raised serum AFP. Survival
curves were compared using the logrank test
(Peto etal., 1977). Multivariate analysis ofthe
effects of several factors simultaneously on
survival was carried out using the regression
method ofCox (1972).
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FIG. 1.-Simple actuarial survival curves
(Berkson-Gage method) for total series,
separated into those with (O) and without
(*) raised serum AFP.
those with normal and those with raised
AFP (X2=6616, d.f.=1, P<0.025). The
percentages of survivors at one year were
81% and 12% respectively. In the non-
cirrhotic group, 16 patients had normal
and 12 had raised serum AFP. The mean
age (40 years) was the same in both groups
and 25% of those with raised and 21% of
thosewithnormalserum AFPweretreated
surgically. Cytotoxic drugs given in 50%
and 84% respectively. Simple actuarial
survival curves (Fig. 2) within this sub-
group of non-cirrhotic patients showed
that 81% of those with normal and 48%
of those with raised serum AFP survived
for one year (x2=019, P=0.66).
Of those patients with raised serum
AFP, 29 had underlying cirrhosis and 12
100
RESULTS
The 41 patients with raised and 16 with
normal serum AFP had mean ages of 56
and 40 years respectively, a difference
which was statistically significant (t=
3-18, P < 0-01). There was no significant
difference between the percentage ofthose
who had been treated surgically (15%
and 31% respectively) and those who had
received cytotoxic drugs (85% and 65%
respectively). Actuarial survival curves
(Fig. 1) showed a statistically highly sig-
nificant difference in survival between
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FIG. 2.-Actuarial survival curves for non-
cirrhotic patients, separated into those
with (U) and without (LO) raised serum
AFP.
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FiG. 3. Actuarial survival curves for patients
with raised serum AFP, divided according
to presence (O-i) or absence (-) of under-
lying cirrhosis.
were non-cirrhotic. The mean age of the
former was 64 years compared with 40
years in the patients without cirrhosis, a
difference which was not significant. Ten
per cent of those with cirrhosis and 25%
of the non-cirrhotics had surgery, whilst
92% and 83% respectively were treated
with cytotoxic drugs. Actuarial survival
curves (Fig. 3) showed a highly significant
difference in survival between those with
and those without underlying cirrhosis
(X2 = 6-64, P<0.01).
Sex was not a significant prognostic
factor (P=0-11). Three factors were asso-
ciated with significantly prolonged sur-
vival; the absence of cirrhosis (Z=4-11,
P<0-001), age less than 50 (Z=2-84,
P <0u02), normal AFP (Z = 3-17, P < 0-01).
Furthermore, patients with low AFP
levels survived longer than those with
moderately raised levels and they in turn
survived longer than those with markedly
raised levels (log-rank test for trend,
P < 0 02). However, multivariate regres-
sion analysis (Cox, 1972) showed that the
TABLE.-Relationship between prognostic
factors and presence or absence of under-
lying cirrhosis
Cirrhotic
(%)
Raised serum AFP 100
>50 years 100
Male sex 93
Non-
cirrhotic
(0/0)
43
36
57
absence of cirrhosis was a favourable
prognostic factor which by itself
adequately explained the variation in
survival time, whereas other factors, in-
cluding normal serum AFP and youth,
were less closely correlated with prolonged
survival and were associated with the
non-cirrhotic state (Table).
DISCUSSION
One notable feature of the present
series is the considerable number of non-
cirrhotic patients 4900 in the total series.
This is a rather higher percentage than in
other series reported from this country
(MacSween, 1974), and may reflect a bias
in referral to the Liver Unit of the more
unusual cases. It has, however, allowed us
to determine whether a true relationship
exists between serum AFP and survival.
Although in any such analysis the series
of patients should have been followed up
without the effects of medical or surgical
treatment, this could not now be justified
ethically. However, the therapeutic frame-
work adopted (surgical removal of tumour
or the most effective currently available
chemotherapy in the remainder) was
applied similarly to both groups, and the
more favourable survival of those with
normal AFP was still immediately ap-
parent. Survival was also better in the
non-cirrhotic patients, but in this group
the percentage of those with normal AFP
washigher than in the cirrhotic patients.
With multivariate analysis it is possible
to determine whether cirrhosis or the AFP
level is the more important. Using the
Cox regression analysis it was shown that
although a normal serum AFP, as well
as the occurrence of disease at a younger
age, correlate with a favourable prognosis,
this might be because of their relationship
with the one significant diagnostic deter-
minant, the presence or absence of cirrho-
sis. Thus, the shortened survival time
found in patients with raised serum AFP
may be due to the greater likelihood of
this group of patients having an under-
lying cirrhosis.
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In contrast, studies from high-incidence
areas such as Japan (Okuda, 1976) and
Uganda (Primack et al., 1975) do not show
that the presence ofunderlying cirrhosis is
associated with a worse prognosis. But
this may be explained by a basic difference
in the natural history of hepatocellular
carcinoma between such areasandWestern
Europe, where the tumour is much less
common. In a study of 75 patients in
Uganda (Primacketal., 1975),theinfluence
of cirrhosis was assessed by comparing its
frequency in those who survived for less
than 2 months and for longer. No sig-
nificant difference was found. Only 30%
of the total series of patients were alive
at one month and 20% at two monthsfrom
diagnosis,whereasover 80% ofourpatients
survived for 2 months and 36% were alive
at one year. A further difference is that
while the presence or absence of cirrhosis
was confirmed in all the patients in our
study, this was so in only 40% ofthe cases
in the Ugandan series. As the authors
point out, the disease seen in Ugandans
and in the South African Bantu (Provan
et al., 1968) appears to be rapidly progres-
sive, with a short duration of symptoms
before diagnosis and a fulminating clinical
course to death.
In the Western European patient with
hepatocellular carcinoma, cirrhosisappears
to exert an adverse effect, but whether
this is simply an indication of the com-
bined effects of hepatocellular decompen-
sation from cirrhosis and the presence of
expanding tumour, orwhetherthetumours
which arise in this group are of greater
intrinsic malignancy, is difficult to deter-
mine.
This work was supported by a grant from the
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